🇺🇸 recombinant human interferon Alpha-1b in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 10

Most-reported reactions

1. Off Label Use — 2 reports (20%)
2. Tonsillitis — 2 reports (20%)
3. Cough — 1 report (10%)
4. Dyspnoea — 1 report (10%)
5. Lung Opacity — 1 report (10%)
6. Oropharyngeal Pain — 1 report (10%)
7. Sars-Cov-2 Antibody Test Positive — 1 report (10%)
8. Treatment Failure — 1 report (10%)

Source database →

Frequently asked questions

Is recombinant human interferon Alpha-1b approved in United States?

recombinant human interferon Alpha-1b does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for recombinant human interferon Alpha-1b in United States?

Shanghai Jiao Tong University School of Medicine is the originator. The local marketing authorisation holder may differ — check the official source linked above.